Cinzia Cavestro1, Diana Degan2, Gianmatteo Micca3,4, Raffaele Aloi5, Silvia Mandrino6, Maria Cristina Frigeri7, Francesca Pistoia2, Filippo Molinari3, Simona Sacco2. 1. Headache Center, Department of Neurology, 'San Lazzaro' Hospital, ASL CN2, Alba, Italy. cicaves@alice.it. 2. Institute of Neurology, Department of Applied Clinical Sciences and Biotechnology, University of L'Aquila, L'Aquila, Italy. 3. Main Laboratory and Hematology and Coagulation Disorders Laboratory, ASL CN2, Alba, Italy. 4. Main Laboratory and Hematology and Coagulation Disorders Laboratory, 'Santa Croce' Hospital, Cuneo, Italy. 5. Occupational Medicine Service, ASL CN2, Alba, Italy. 6. Headache Center, Department of Neurology, 'San Lazzaro' Hospital, ASL CN2, Alba, Italy. 7. Administrative Medical Office, 'San Lazzaro' Hospital, ASL CN2, Alba, Italy.
Abstract
BACKGROUND: The association between thrombophilic alterations, migraine, and vascular events has been broadly investigated but not been completely clarified. METHODS: In this cross-sectional, case-control study, we included consecutive outpatients diagnosed with migraine referring to a tertiary headache center. Migraine patients were matched to headache-free control subjects. All participants were evaluated for free protein S anticoagulant, functional protein C anticoagulant, homocysteine, and antiphospholipid antibodies (aPLs). History of ischemic stroke (IS) or transient ischemic attack (TIA), coronary heart disease, and peripheral venous thrombosis was also ascertained. RESULTS: We included 329 migraine patients and 329 control subjects (mean age 41 years, 77% women in both groups). Among migraine patients, 239 (72.6%) had migraine without aura and 90 (27.4%) had migraine with aura. Migraine patients had more frequently arterial hypertension, hypercholesterolemia, history of IS or TIA and, peripheral venous thrombosis compared to control subjects, whereas we found no differences in diabetes mellitus, BMI, and coronary heart disease between the two groups. At least one thrombophilic alteration was detected in 107 (32.5%) migraine patients and in 74 (22.5%) control subjects (OR = 1.66, 95% CI 1.17-2.35, p = 0.004). We identified an association of migraine with aPL positivity (OR = 2.6, 95% CI 1.5-4.7, p = 0.001) and with free protein S deficiency (OR = 4.7, 95% CI 1.6-14.0, p = 0.002), whereas we found no differences in protein C deficiency, APCR, and hyperhomocysteinemia between the two groups. Furthermore, aPL positivity and free protein S deficiency were more common in migraine patients with and without aura than in control subjects. We found that in migraine patients, aPL positivity was associated with both IS or TIA (OR = 5.6, 95% CI 1.5-20.4, p = 0.009) and with coronary heart disease (OR = 27.6, 95% CI 1.4-531.1, p = 0.028), whereas free protein S deficiency was associated with IS or TIA only (OR = 14.3, 95% CI 2.8-74.4, p = 0.002). CONCLUSIONS: Our research documented a significative higher prevalence of aPL positivity and protein S deficiency in migraineurs than in controls. Data also showed an association between these alterations and some vascular thrombotic events in migraine patients. We can argue that thrombophilic disorders associated with migraine may contribute to the occurrence of vascular events.
BACKGROUND: The association between thrombophilic alterations, migraine, and vascular events has been broadly investigated but not been completely clarified. METHODS: In this cross-sectional, case-control study, we included consecutive outpatients diagnosed with migraine referring to a tertiary headache center. Migrainepatients were matched to headache-free control subjects. All participants were evaluated for free protein S anticoagulant, functional protein C anticoagulant, homocysteine, and antiphospholipid antibodies (aPLs). History of ischemic stroke (IS) or transient ischemic attack (TIA), coronary heart disease, and peripheral venous thrombosis was also ascertained. RESULTS: We included 329 migrainepatients and 329 control subjects (mean age 41 years, 77% women in both groups). Among migrainepatients, 239 (72.6%) had migraine without aura and 90 (27.4%) had migraine with aura. Migrainepatients had more frequently arterial hypertension, hypercholesterolemia, history of IS or TIA and, peripheral venous thrombosis compared to control subjects, whereas we found no differences in diabetes mellitus, BMI, and coronary heart disease between the two groups. At least one thrombophilic alteration was detected in 107 (32.5%) migrainepatients and in 74 (22.5%) control subjects (OR = 1.66, 95% CI 1.17-2.35, p = 0.004). We identified an association of migraine with aPL positivity (OR = 2.6, 95% CI 1.5-4.7, p = 0.001) and with free protein S deficiency (OR = 4.7, 95% CI 1.6-14.0, p = 0.002), whereas we found no differences in protein C deficiency, APCR, and hyperhomocysteinemia between the two groups. Furthermore, aPL positivity and free protein S deficiency were more common in migrainepatients with and without aura than in control subjects. We found that in migrainepatients, aPL positivity was associated with both IS or TIA (OR = 5.6, 95% CI 1.5-20.4, p = 0.009) and with coronary heart disease (OR = 27.6, 95% CI 1.4-531.1, p = 0.028), whereas free protein S deficiency was associated with IS or TIA only (OR = 14.3, 95% CI 2.8-74.4, p = 0.002). CONCLUSIONS: Our research documented a significative higher prevalence of aPL positivity and protein S deficiency in migraineurs than in controls. Data also showed an association between these alterations and some vascular thrombotic events in migrainepatients. We can argue that thrombophilic disorders associated with migraine may contribute to the occurrence of vascular events.
Entities:
Keywords:
Antiphospholipid antibodies; Hematologic diseases; Migraine disorders; Protein S deficiency; Stroke; Thrombophilias
Authors: Michel D Ferrari; Roselin R Klever; Gisela M Terwindt; Cenk Ayata; Arn M J M van den Maagdenberg Journal: Lancet Neurol Date: 2015-01 Impact factor: 44.182
Authors: D D'Amico; F Moschiano; M Leone; C Ariano; E Ciusani; N Erba; L Grazzi; A Ferraris; F Schieroni; G Bussone Journal: Cephalalgia Date: 1998-11 Impact factor: 6.292